An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data

Ribociclib (LEE011, Kisqali ®) is a highly selective small molecule inhibitor of cyclin‐dependent kinases 4 and 6 (CDK4/6), which has been approved for the treatment of advanced or metastatic breast cancer. A human ADME study was conducted in healthy male volunteers following a single oral dose of 6...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Alexander D., Schiller, Hilmar, Marvalin, Cyrille, Jin, Yi, Borell, Hubert, Roffel, Ad F., Glaenzel, Ulrike, Ji, Yan, Camenisch, Gian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287031/
https://www.ncbi.nlm.nih.gov/pubmed/32524755
http://dx.doi.org/10.1002/prp2.599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287031/
https://www.ncbi.nlm.nih.gov/pubmed/32524755
http://dx.doi.org/10.1002/prp2.599

Ejemplares similares